The first time this got near FDA approval, CXS was not going ONLY for approval for patients who had failed (one or two?) other treatments.Does anyone know how much this affects their potential market sizes compared with the original application?
Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks
AN1 CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch